Extending the time window for stroke treatment: Advanced brain imaging ± bat saliva

International Journal of Stroke

Volumn 4, Issue 2, 2009, Pages 94-96

  De Georgia, Michael ^a,b,c  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

Ischemia; MRI; Stroke; Thrombolysis; Tissue plasminogen activator

Indexed keywords

ALTEPLASE; DESMOTEPLASE; FIBRINOLYTIC AGENT; PLACEBO; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE DISEASE; ACUTE HEART INFARCTION; ARTICLE; BLEEDING; BRAIN BLOOD FLOW; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN RADIOGRAPHY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIFFUSION WEIGHTED IMAGING; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG MEGADOSE; EARLY INTERVENTION; ENDOTHELIUM LESION; FIBRINOLYTIC THERAPY; HUMAN; INTERVENTIONAL RADIOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PERFUSION WEIGHTED IMAGING; PRIORITY JOURNAL; SYMPTOM; TREATMENT OUTCOME;

ANIMALS; BRAIN; CHIROPTERA; DIAGNOSTIC IMAGING; FIBRINOLYTIC AGENTS; HUMANS; PLASMINOGEN ACTIVATORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SALIVA; STROKE; THROMBOLYTIC THERAPY; TIME;

EID: 65449128845     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/j.1747-4949.2009.00257.x     Document Type: Article

References (13)

1. Tissue plasminogen activator for acute ischemic stroke: The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333:1581-7.
2. Parsons MW, Barber PA, Chalk J et al. Diffusion- and perfusion-weighted MRI response to thrombolysis in stroke. Ann Neurol 2002; 51:28-37.
3. Warach S. Thrombolysis in stroke beyond three hours: Targeting patients with diffusion and perfusion MRI. Ann Neurol 2002; 51:11-3.
4. Thomalla G, Schwark C, Sobesky J et al. Outcome and symptomatic bleeding complications of intravenous thrombolysis within 6 hours in MRI-selected stroke patients: Comparison of a German multicenter study with the pooled data of ATLANTIS, ECASS, and NINDS tPA trials. Stroke 2006; 37:852-8.
5. Kohrmann M, Juttler E, Fiebach JB et al. MRI versus CT-based thrombolysis treatment within and beyond the 3 hour time window after stroke onset: A cohort study. Lancet Neurol 2006; 5:661-7.
6. Lansberg MG, Thijs VN, Hamilton S et al. Evaluation of the clinical-diffusion and perfusion-diffusion mismatch models in defuse. Stroke 2007; 38:1826-30.
7. Davis S, Donnan GA. Breaking the 3h barrier for treatment of acute ischaemic stroke. Lancet Neurol 2008; 7:981-2.
8. Nicole O, Docagne F, Ali C et al. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med 2001; 7:59-64.
9. Reddrop C, Moldrich RX, Beart FM et al. Vampire bat salivary plasminogen activator (desmoteplase) inhibits tissue-type plasminogen activator-induced potentiation of excitotoxic injury. Stroke 2005; 36:1241-6.
10. Liberatore GT, Samson A, Bladin C, Schleuning W-D, Medcalf RL. Vampire bat salivary plasminogen activator (desmoteplase): A unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke 2003; 34:537-43.
11. Hacke W, Albers G, Al-Rawi Y et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): A phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005; 36:66-73.
12. Furlan AJ, Eyding D, Albers GW et al. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): Evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 2006; 37:1227-31.
13. Warach S for the DIAS-2 Study Group. Clinical benefit of desmoteplase treatment in patients with moderate to severe stroke-further results of the DIAS-2 study. Presented at the 2008 International Stroke Conference. February 22, 2008. New Orleans, LA.